Patents by Inventor Lane D. Foil

Lane D. Foil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230276802
    Abstract: Modulation of inward potassium ion conductance with structurally diverse small-molecules in the arthropod salivary gland induces arthropod salivary gland failure that results in a reduction or elimination in the ability of the arthropod to feed. Administering Kir channel inhibitors reduces food intake, increases feeding time, reduces salivary gland secretion, induces mortality, and reduces transmission of vector-borne pathogens. Kir channel inhibitors induce these adverse effects in ticks, mosquitoes, horn flies, and aphids.
    Type: Application
    Filed: April 20, 2023
    Publication date: September 7, 2023
    Applicant: Board of Supervisors of Louisiana State Universtiy and Agricultural and Mechanical College
    Inventors: Daniel R. Swale, Lane D. Foil
  • Patent number: 11632953
    Abstract: Modulation of inward potassium ion conductance with structurally diverse small-molecules in the arthropod salivary gland induces arthropod salivary gland failure that results in a reduction or elimination in the ability of the arthropod to feed. Administering Kir channel inhibitors reduces food intake, increases feeding time, reduces salivary gland secretion, induces mortality, and reduces transmission of vector-borne pathogens. Kir channel inhibitors induce these adverse effects in ticks, mosquitoes, horn flies, and aphids.
    Type: Grant
    Filed: November 13, 2017
    Date of Patent: April 25, 2023
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Daniel R. Swale, Lane D. Foil
  • Publication number: 20190320655
    Abstract: Modulation of inward potassium ion conductance with structurally diverse small-molecules in the arthropod salivary gland induces arthropod salivary gland failure that results in a reduction or elimination in the ability of the arthropod to feed. Administering Kir channel inhibitors reduces food intake, increases feeding time, reduces salivary gland secretion, induces mortality, and reduces transmission of vector-borne pathogens. Kir channel inhibitors induce these adverse effects in ticks, mosquitoes, horn flies, and aphids.
    Type: Application
    Filed: November 13, 2017
    Publication date: October 24, 2019
    Applicant: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Daniel R. Swale, Lane D. Foil
  • Patent number: 10363292
    Abstract: Compositions of either the Rm86Texas protein from a Texas outbreak strain of the southern cattle fever tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this Rm86Texas protein, are effective for eliciting a protective immune response in non-bovine animals. The Rm86Texas protein is immunogenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks. Moreover, as ticks are vectors of a variety of pathogens, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogens in susceptible animals.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: July 30, 2019
    Assignees: The United States of America, as Represented by the Secretary of Agriculture, Board of Supervisors of Louisiana State University and Agriculture and Mechanical Colloge
    Inventors: Andrew Y. Li, Felicito Guerrero, Lane D. Foil, Adalberto A. Perez De Leon
  • Publication number: 20180085443
    Abstract: Compositions of either the Rm86Texas protein from a Texas outbreak strain of the southern cattle fever tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this Rm86Texas protein, are effective for eliciting a protective immune response in non-bovine animals. The Rm86Texas protein is immunogenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks. Moreover, as ticks are vectors of a variety of pathogens, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogens in susceptible animals.
    Type: Application
    Filed: September 18, 2017
    Publication date: March 29, 2018
    Inventors: ANDREW Y. LI, FELICITO GUERRERO, LANE D. FOIL, ADALBERTO A. PEREZ DE LEON
  • Patent number: 9408896
    Abstract: Compositions of either the aquaporin protein from the cattle tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this aquaporin protein, are effective for eliciting a protective immune response against other tick species in non-bovine animals. The R. microplus aquaporin protein is antigenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks other than the cattle tick, particularly the brown dog tick, Rhipicephalus sanguineus. Moreover, as ticks are vectors of a variety of pathogenic agents, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogenic agents in susceptible animals.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: August 9, 2016
    Assignees: The United States of America, as represented by the Secretary of Agriculture, Louisiana State University Agricultural Center
    Inventors: Felicito Guerrero, Adalberto A. Perez De Leon, Lane D. Foil
  • Publication number: 20140271702
    Abstract: Compositions of either the aquaporin protein from the cattle tick, Rhipicephalus microplus, or a nucleic acid construct incorporating a nucleic acid sequence encoding this aquaporin protein, are effective for eliciting a protective immune response against other tick species in non-bovine animals. The R. microplus aquaporin protein is antigenic and can be administered as a protein vaccine, or in the alternative, the nucleic acid construct can be utilized as a DNA vaccine. Induction of the immune response significantly reduces or eliminates the infestation of treated, non-bovine animals with ticks other than the cattle tick, particularly the brown dog tick, Rhipicephalus sanguineus. Moreover, as ticks are vectors of a variety of pathogenic agents, the reduction in the incidence of tick infestation afforded by the vaccines may concurrently reduce the incidence of diseases caused by these pathogenic agents in susceptible animals.
    Type: Application
    Filed: March 7, 2014
    Publication date: September 18, 2014
    Inventors: Felicito Guerrero, Adalberto A. Perez De Leon, Lane D. Foil
  • Patent number: 8258100
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: September 4, 2012
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
  • Publication number: 20100016227
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Application
    Filed: June 19, 2009
    Publication date: January 21, 2010
    Applicant: BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHNICAL COLLEGE
    Inventors: FREDERICK M. ENRIGHT, JESSE M. JAYNES, WILLIAM HANSEL, KENNETH L. KOONCE, SAMUEL M. MCCANN, WEN H. YU, PATRICIA A. MELROSE, LANE D. FOIL, PHILIP H. ELZER
  • Patent number: 7566777
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Grant
    Filed: July 11, 2003
    Date of Patent: July 28, 2009
    Assignee: Board of Supervisors of Louisana State University and Agricultural and Mechanical College
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
  • Publication number: 20090047235
    Abstract: A paratransgenesis system is disclosed to kill targeted social insects such as termites and cockroaches, for example the Formosan subterranean termite. A genetically modified yeast can be effectively used to express and deliver lytic peptides directly within the termite gut. Some highly lytic peptides directly damage the insect gut itself, leading to the death of the insect within about three days. Other lytic peptides kill all (or at least most) species of protozoa in the termite gut. The protozoa provide wood-digesting enzymes (cellulases) to the termite. Without these protozoa (and their cellulases) the insect dies within about six weeks. The system is completely free from conventional neurotoxins and other organic pesticides.
    Type: Application
    Filed: May 15, 2008
    Publication date: February 19, 2009
    Inventors: Claudia R. Husseneder, James A. Ottea, Lane D. Foil, Frederick M. Enright, Richard K. Cooper
  • Publication number: 20040018967
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Application
    Filed: July 11, 2003
    Publication date: January 29, 2004
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer
  • Patent number: 6635740
    Abstract: Amphipathic lytic peptides are ideally suited to use in a ligand/cytotoxin combination to specifically inhibit cells that are driven by or are dependent upon a specific ligand interaction; for example, to induce sterility or long-term contraception, or to attack tumor cells, or to selectively lyse virally-infected cells, or to attack lymphocytes responsible for autoimmune diseases. The peptides act directly on cell membranes, and need not be internalized. Administering a combination of gonadotropin-releasing hormone (GnRH) (or a GnRH agonist) and a membrane-active lytic peptide produces long-term contraception or sterilization in animals in vivo. Administering in vivo a combination of a ligand and a membrane-active lytic peptide kills cells with a receptor for the ligand. The compounds are relatively small, and are not antigenic. Lysis of gonadotropes has been observed to be very rapid (on the order of ten minutes.) Lysis of tumor cells is rapid.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: October 21, 2003
    Assignee: Board of Supervisors of Louisiana State University and Agricultural and Mechanical College
    Inventors: Frederick M. Enright, Jesse M. Jaynes, William Hansel, Kenneth L. Koonce, Samuel M. McCann, Wen H. Yu, Patricia A. Melrose, Lane D. Foil, Philip H. Elzer